Reviewer's report

Title: Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison

Version: 3 Date: 22 November 2013

Reviewer: Sang-Hyuk Lee

Reviewer's report:

Major Compulsory Revisions

This study examined the cost-effectiveness comparison between OLAI and RLAI in Spain. Present results proposed the interesting point of the treatment with long-acting antipsychotics in patients with schizophrenia. However, there are unclear parts in current manuscript.

1. The authors should clarify that subjects in both groups are not clinically different before RLAI or OLAI treatment. For example, if the clinical characteristics (such as psychotic symptoms, negative/cognitive symptoms, insights, compliance, duration of illness, etc.) of RLAI group were much worse than those of OLAI group before receiving long-acting antipsychotics, the comparison would be influenced by the difference of those factors.

2. The authors should consider to include other concomitant medications or cost of therapy associated with metabolic syndrome in patient with schizophrenia. Actually, with atypical antipsychotics, side effects such as obesity, lipidemia, or glucose intolerance (other than EPS) could be more problematic in long-term follow-up. It would be better to include the medical cost of metabolic syndrome after RLAI or OLAI treatment in your model.

Level of interest: An article of limited interest

Quality of written English: Needs some language corrections before being published

Statistical review: Yes, but I do not feel adequately qualified to assess the statistics.

Declaration of competing interests:

I declare that I have no competing interests.